Day: March 27, 2020

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – Sigma Labs Inc. (NASDAQ: SGLB)  announces the availability of a broadcast titled, “Transformative Software Unleashes 3D Printing Industry.”To hear the AudioPressRelease from NetworkNewsAudio, visit: http://nnw.fm/dgG0DTo read the full editorial, visit: http://nnw.fm/Ngl0VThe full promise of 3D metal printing is imminent as long-sought quality-control systems provide newfound ability to scale additive metal manufacturing.From its inception by scientists at Los Alamos, Sigma Labs Inc. (NASDAQ: SGLB) has led the world in developing software that addresses serious quality-assurance issues in 3D metal printing. Now the company has moved from beta development and third-party validation to commercialization in an untapped $2 billion market as the only known provider of...

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) — With the COVID-19 pandemic escalating in the U.S., SCWorx Corp. (Nasdaq: WORX) announced today an agreement between its subsidiary Direct Worx and an existing large hospital customer to supply one million surgical masks, which were fulfilled and shipped yesterday. The initial agreement was for $390,000, with additional potential agreements to help hospitals source urgently needed Personal Protective Equipment (PPE) are anticipated.“Hospitals are quickly running out of surgical masks and other PPE as the number of COVID-19-infected patients accelerates beyond hospitals’ ability to procure needed PPE to protect patients, doctors, nurses and other hospital personnel treating infected patients,” said Marc Schessel, CEO of SCWorx. “Our subsidiary, Direct Worx utilizes our extensive hospital...

Nominees Include James J. Martell and James L. WelchCompany Announces Agreement with Saddle Point Management, L.P.BANNOCKBURN, Ill., March 27, 2020 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) (“Stericycle” or the “Company”) today announced that its Board of Directors has agreed to nominate James J. Martell (“Jim”), former Chief Executive Officer of Express-1, the predecessor company to XPO Logistics, and James L. Welch, former Chief Executive Officer of YRC Worldwide, as director nominees to stand for election to the Board at the Company’s 2020 Annual Meeting of Stockholders.The director nominations follow ongoing discussions with Saddle Point Management, L.P. (“Saddle Point”), a current investor in the Company. In connection with the Board’s agreement to nominate Mr. Martell and Mr. Welch, Stericycle and Saddle Point have...

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – InsuraGuest Technologies Inc. (TSX.V: ISGI) announces the availability of a broadcast titled, “Growing Vacation Industry Fosters Demand for Integrated Support Services.”To hear the AudioPressRelease from NetworkNewsAudio, visit:  http://nnw.fm/J69Zn.To read the full editorial, visit: http://nnw.fm/Is8lC.In the United States alone, an estimated 4.5 million second homes are managed by rental companies. Every day, travelers turn to agents to help them with the administration of holiday and vacation travel. InsuraGuest Technologies Inc. (TSX.V: ISGI) was established to provide a vital part of that vacation ecosystem.Any player in the vacation industry faces the risk of liability in the event of guests injuring themselves. Additional features and facilities, which are...

SCANFIL OYJ      PÖRSSITIEDOTE       27.3.2020   KLO 14:30Hallituksen puheenjohtajaksi valittaisiin edelleen Harri Takanen.27.3.2020LiitePalkitsemispolitiikka_Scanfil Oyj

In its financial statements published on 7 February 2020, Martela Oyj estimated its turnover and operating result in 2020 to be slightly higher than in the previous year.The company now estimates that the ongoing coronavirus pandemic has significantly weakened the outlook in all market areas, and it is highly unlikely that the company’s earlier guidance will actualise.Martela will withdraw its 7 February 2020 outlook due to the estimated impact of the coronavirus pandemic. Due to the prevailing circumstances, it is not possible to make an accurate estimate of the company’s full-year turnover and operating result. Martela will publish a guidance for 2020 once a reliable estimate on the impacts can be made.These are exceptional times with the coronavirus spreading around the world. The health and wellbeing of our employees and...

Martela Oyj arvioi 7.2.2020 julkaistussa tilinpäätöstiedotteessaan liikevaihdon ja liiketuloksen vuonna 2020 olevan edellisvuotista hieman korkeampi.Martela OyjMatti RantaniemiCEOLisätiedotMatti Rantaniemi, CEO, puh. +358 50 465 8194Kalle Lehtonen, Talousjohtaja +358 400 539 968JakeluNasdaq OMX HelsinkiKeskeiset tiedotusvälineetwww.martela.comMissiomme ”better working” ja visiomme ”people centric workplaces” määrittelevät strategisen suuntamme. Martela toimittaa käyttäjälähtöisiä työympäristöjä, joissa käyttäjät ja heidän hyvinvointi ovat keskiössä. Keskitymme Pohjoismaihin, sillä yhteisen avoimen työkulttuuritaustamme ja tarpeidemme myötä Pohjoismaat ovat hybridien työympäristöjen edelläkävijöitä.

The Board of Directors of Data Respons ASA approved the annual report for 2019 on 26 March 2020. There are no significant changes compared to the preliminary financial statements for 2019 published on 30 January 2020 at the Q4 2019 presentation. The Annual Report is subject to approval by the annual general meeting.A PDF-version of the annual report is attached and is also available on our webpage: www.datarespons.com/investors For further information: Kenneth Ragnvaldsen, CEO, Data Respons ASA, tel. +47 913 90 918.Rune Wahl, CFO, Data Respons ASA, tel. + 47 950 36 046

PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.About Passage BioPassage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development,...